
Open this photo in gallery:
The Competition Bureau did not find wrongdoing in its investigation of Express Scripts, but says preferred provider networks could raise issues in other cases.Jacques Boissinot/The Canadian Press
The federal Competition Bureau has concluded an investigation into Express Scripts Canada, a large player in managing insurance claims at drugstore checkouts, saying it found insufficient evidence of wrongdoing but “remains concerned about the potential harm to competition” resulting from deals to steer patients to particular pharmacies.
Express Scripts is the country’s largest “pharmacy benefit manager,” a commonly used middleman between pharmacies and insurers.
PBMs process claims for insurers, which means that drug coverage can be applied at a pharmacy checkout, and customers with insurance do not have to pay out of pocket for the full costs of their drugs.
Pharmacy benefit managers also sometimes set up or manage “preferred provider networks,” a controversial type of deal between insurers and pharmacies that can require people to visit a certain pharmacy in order to be reimbursed for their medications.
Express Scripts Canada is a subsidiary of U.S.-based Express Scripts Holding Co., which is owned by U.S. insurance company Cigna Group. The company also operates mail-order pharmacies in Canada.
In early 2024, the bureau began receiving complaints claiming Express Scripts was abusing its dominance of the market by imposing mandatory fees on retail pharmacies. Complaints also raised concerns about the growth of preferred provider networks in Canada. The watchdog launched its investigation in response.
The investigation looked into two different questions: first, did Express Scripts use PPN deals to force patients to fill prescriptions at its own mail-order pharmacies or associated pharmacies, rather then their pharmacy of choice? And did Express Scripts “squeeze” competing pharmacies’ profits by imposing fees for its PBM services, or through auditing practices? Pharmacists had complained that these audits in some cases clawed back reimbursement claims for prescriptions that were previously verified.
In late 2024, the Competition Bureau also made a submission to an Ontario government consultation into PPNs, expressing concerns that exclusive PPN deals could reduce Canadians’ choice in “a crucial area of health care,” and could make it harder for pharmacies outside PPN networks to stay in business.
“Based on the evidence gathered, the bureau found insufficient evidence at this time to conclude that Express Scripts abused a dominant position,” the federal watchdog wrote in a policy statement released on Monday.
The evidence gathered by the bureau showed that Express Scripts pharmacies account for a small share of prescriptions in Canada, and that its PPNs are not widely used here.
It also found there was not enough evidence to show the company’s fees harmed competition.
“While the bureau did not find Express Script’s practices with respect to preferred provider networks were an abuse of dominance, in other cases these networks may raise issues under the Competition Act,” the statement said. “If new information comes to light suggesting that a preferred provider network braises issues under the Competition Act, the bureau will not hesitate to take appropriate enforcement action.”
Express Scripts welcomed the investigation’s conclusion on Monday.
The company “has consistently maintained that its role is to help make prescription drugs more affordable and accessible,” said a statement provided by chief human resources and privacy officer Stéphanie Myner-Nham. “ESC remains focused on supporting reliable access to medications for Canadians, lowering costs for patients and plan sponsors, and working constructively with pharmacies across Canada.”
Peter Saad, managing partner of Loopstra Nixon LLP, said Express Scripts holds a unique place in the industry over its rivals because it both operates its own pharmacy services and processes claims at other pharmacies. The company also audits those claims and can refer pharmacists to a provincial regulator or revoke a pharmacy’s billing privileges, making it difficult to see some patients. “You’re being supervised by your competitor,” he said.
While announcing the conclusion of the investigation, the Competition Bureau also provided guidance to the industry about PPNs, noting these deals “can raise competition concerns when they exclude or disadvantage rival pharmacies.”
It noted that PPNs are most likely to raise competition concerns when one or more of the companies involved have market power – such as a large insurer, pharmacy chain or PBM – and can therefore steer a large number of patients toward certain services.
Concerns are also likely when companies operate on various levels of the prescription drug supply chain (such as when a PPN operator owns its own pharmacies) and when PPNs limit other pharmacies’ access to patients.
“The more a network incentivizes, or even requires, patients to use in-network pharmacies, the more likely it is to impact patient behaviour and shift prescriptions away from rival pharmacies,” the statement said. “As patient volumes fall, affected pharmacies may face higher costs and may need to spend more to retain customers or remain competitive. These pressures can weaken competition even if those pharmacies remain in the market.”
Mandatory PPNs like this are “more likely to prompt investigation,” it noted.
The Canadian Pharmacists Association, which submitted a complaint against Express Scripts in 2024, wrote in a statement on Monday that it was disappointed with the results of the investigation, but encouraged by the bureau’s guidance to the industry.
The pharmacists’ group called on federal, provincial and territorial governments to strengthen the rules around how pharmacy benefit managers operate, and to curb the spread of mandatory and exclusive PPNs.
“Canada has an opportunity to establish safeguards before potentially restrictive arrangements become more widespread, informed by this guidance and lessons from the United States,” it said in a press release.